Sucampo names Peter Greenleaf to chief executive post

Bethesda-based Sucampo named former MedImmune president Peter Greenleaf to serve as the company’s chief executive starting next month, according to a news release.

The appointment brings a high-profile name to the biotechnology firm as it looks to commercialize products for glaucoma and constipation, as well as develop additional drugs to treat eye and digestive issues.

Greenleaf will replace Sucampo co-founder Ryuji Ueno, who will remain a scientific adviser to the company on a one-year, renewable contract, according to the statement.

Dan Getman will replace Ueno as the firm’s chairman.

“Peter’s expertise in growing biopharmaceutical companies, including experience leading a gastroenterology business, will be a valuable addition to Sucampo. The Board is confident that under his leadership Sucampo’s legacy of growth will be accelerated,” Getman said.

Greenleaf was replaced as MedImmune’s president by Bahija Jallal last January when parent corporation AstraZeneca made the Gaithersburg-based company its global hub for biologics research and development. Jallal is a scientist, Greenleaf is a businessman.

Greenleaf most recently served as president and chief executive of Histogenics, a regenerative medicine company in Waltham, Mass.

Ueno and his wife Sachiko Kuno attracted attention after purchasing the Evermay estate in Georgetown in late 2011 with plans to establish a chartible foundation there.

Steven Overly covers the business of technology, biotechnology and venture capital in the Washington region for The Washington Post and its weekly Capital Business publication. In that capacity, he has written about start-up struggles, investment trends and major drug discoveries.
Comments
Show Comments
Most Read Business